Atrial Fibrillation – Epidemiology – Mature Markets Data

Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of AF for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities are also forecast across the major pharmaceutical markets.

Clarivate Epidemiology’s AF forecast will answer the following questions:

  • How will change in the levels of exposure to known risk or protective factors affect the number of people living with AF?
  • Of all people with AF, how many in each country across the world have been formally diagnosed?
  • Of all people diagnosed with AF, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AF over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides at least twenty years of forecast data for the following AF patient populations:

  • Total AF prevalent cases.
  • Diagnosed AF prevalent cases.
  • Undiagnosed AF prevalent cases.
  • Diagnosed AF prevalent cases by subtype scheme.
  • Diagnosed AF prevalent cases by hypertension status.
  • Diagnosed AF prevalent cases by valvular heart disease status.
  • Diagnosed AF prevalent cases by heart failure status.
  • Diagnosed AF prevalent cases with heart failure NYHA subpopulation(s).
  • Diagnosed AF prevalent cases by CHADS2 score scheme.
  • Diagnosed AF prevalent cases by CHA2DS2-VASc score scheme.
  • Diagnosed AF drug-treated prevalent cases.
  • Diagnosed AF non-drug-treated prevalent cases.
  • Diagnosed AF incident cases.

… and many more (details available on request).

Note: Coverage may vary by country and region.

Table of contents